Johnson & Johnson (JNJ) said Thursday that a phase 3 study of the investigational combination of Tecvayli and Darzalex Faspro in patients with relapsed or refractory multiple myeloma met the primary endpoint of progression-free survival at almost three years of follow-up, with the results found to be "superior" to the current standard of care.

The interim analysis also showed the study achieved statistically significant overall survival outcomes, the secondary endpoint, the company said.

Based on the results, Johnson & Johnson said the independent data monitoring committee recommended unblinding the study.

The company said it plans to submit the data to regulators, positioning the combination therapy as a potential new standard of care for multiple myeloma.

Price: 192.38, Change: +1.21, Percent Change: +0.63